Neko Derma
Proprietary device capturing over 2,000 high-resolution images of skin for comprehensive mole mapping and tracking
Device · On PremiseCompany source
Company profile
About Neko Health
Neko Health is a health technology company founded in 2018 in Stockholm, Sweden, that is redefining preventive healthcare through proprietary technology and clinical innovation. Co-founded by Spotify founder Daniel Ek and engineer Hjalmar Nilsonne, Neko was created to answer a fundamental question: what would healthcare look like if it were designed around keeping people healthy, rather than treating illness? The company has engineered an end-to-end preventive health system from the ground up, including four proprietary devices—Derma, Spectrum, Echo, and Neko Lens—all designed, engineered, and assembled in their Stockholm facility. The Neko Health Scan captures over 2,000 high-resolution skin images, performs comprehensive cardiovascular assessments including arterial analysis and EKG, analyzes blood samples in on-site labs with results in minutes, and measures body composition including visceral fat. The entire process takes under one hour, with results processed instantly and reviewed in an in-depth consultation with a Neko clinician. The company operates multiple locations across the UK (London, Birmingham, Manchester) and Sweden (Stockholm), with plans to launch in New York City in 2026. With a team of over 1,000 professionals—more than half in clinical roles—Neko is backed by experienced technology investors and led by clinical leadership including Chief Medical Officer Dr. Sunita Mishra and Global Medical Director Dr. Nikita Kanani MBE. The company is actively conducting clinical research through partnerships including SCAPIS 2 studies focused on microcirculation, cardiovascular disease, and diabetes complications.
Company description Neko Health official website
Primary marketMedical Imaging & Radiology
Commercial modelCommercial information available on request
Work at Neko Health?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- cardiovascular disease
- chronic disease prevention
- diabetes complications
- melanoma and skin cancer
- metabolic health conditions
Who it serves
- direct-to-consumer health-conscious individuals
- preventive health seekers
Deployment & integration
Cloud Saas · On Premise deployment with recorded integration context.
Geographic context
MarketsSweden · United Kingdom · United States (launching 2026)
Company sourceOfficial website
Company milestones
Platform expansion
NYC launch announced for 2026 (January 2026), Birmingham opening (January 2026), Manchester opening (September 2025), one-year UK anniversary (October 2025), body composition and wearables integration added (June 2026), Dr. Sunita Mishra joined as CMO (March 2026)
Partnerships
Recorded partners
- Danderyd Hospital Sweden
- SCAPIS 2 (Swedish CardioPulmonary bioImage Study)
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Neko Echo
Proprietary cardiovascular assessment device using contactless laser and microwave radars for arterial stiffness and heart function
Device · On PremiseCompany source
Neko Health Scan
Comprehensive preventive health scan capturing millions of data points across skin, heart, blood, and circulation in under one hour
Platform · On PremiseCompany source
Neko Lens
Proprietary imaging device for body composition analysis measuring visceral and body fat without DEXA or MRI
Device · On PremiseCompany source
Neko Member App
Mobile application providing instant access to scan results, health data, action plans, and wearables integration
Software · Cloud SaaSCompany source
Neko Spectrum
Proprietary optical imaging device capturing tissue-level signals in microcirculation for cardiovascular and metabolic assessment
Device · On PremiseCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Primary care has a voice: let's use it.BMJ leader · Aug 10, 2026
Automated measurement of left ventricular ejection time via contactless suprasternal notch laser vibrometry.Scientific reports · Jun 14, 2026
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
99% melanoma survival rate
if caught early through routine skin checks
~50% undiagnosed cardiovascular disease
until heart attack or stroke - Neko aims to detect earlier
Repeat scans show health improvements
data story published November 2025
David (London Member)
Preventive health scan combining advanced technology with human care
Faultless experience combining amazing technology with warm, supportive human care
James (London Member)
Comprehensive preventive health assessment with immediate clinical consultation
Findings presented by GP within 5 minutes of scan completion, described as 'extraordinary' wellcare experience
Shona (London Member)
One-hour comprehensive health assessment
Described as the most valuable hour one could spend on health
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
06 · Company updates
Updates from Neko Health
Recent articles published on Neko Health's official website.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Medical Imaging & Radiology
Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.